🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Apellis Pharmaceuticals executive sells over $3.7m in stock

Published 04/09/2024, 04:27 PM
APLS
-

Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), has recently sold a significant amount of company stock, according to a new SEC filing. The transactions, dated April 8, 2024, show that Deschatelets sold a total of 69,107 shares of common stock, netting over $3.7 million.

The sales were executed at prices ranging from $54.1165 to $54.9152 per share, with the total value of the transactions amounting to approximately $3,743,605. The reported prices represent a weighted average, indicating that the sales were conducted in multiple trades.

In addition to the sales, Deschatelets also acquired 69,107 shares via the exercise of stock options, with each option having a strike price of $3.76. The total value for these transactions was $259,842. It should be noted that these transactions were part of a pre-planned trading arrangement under a 10b5-1 trading plan, which was established on December 8, 2023.

Following these transactions, Deschatelets still holds a substantial position in the company, with 1,115,983 shares of Apellis Pharmaceuticals remaining in his direct ownership.

Investors often monitor insider transactions as they can provide insights into the executives' perspectives on the company's current valuation and future prospects. However, it's important to recognize that insider trading activities can be subject to various personal financial needs and strategies, and not necessarily indicative of corporate performance.

Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, which is a critical component of the immune system.

The company's stock performance and insider transactions are closely watched by investors, as they try to glean insights into the company's operations and potential growth opportunities.

InvestingPro Insights

Amidst the insider trading activities of Apellis Pharmaceuticals' Chief Scientific Officer, Pascal Deschatelets, investors are keen to understand the financial health and market performance of the company. With a market capitalization of $6.65 billion and a dramatic revenue growth of 425.83% in the last twelve months as of Q4 2023, Apellis is showing signs of aggressive expansion in its sector.

Despite the impressive revenue surge, the company's gross profit margin stands at -4.11%, highlighting challenges in profitability. This is further corroborated by an InvestingPro Tip indicating that analysts do not expect the company to be profitable this year. Furthermore, the high Price / Book ratio of 34.17 suggests that the stock is trading at a premium compared to its book value, which is an important consideration for value investors.

On the upside, Apellis' liquid assets surpass its short-term obligations, suggesting a stable liquidity position. This is a crucial metric for investors as it implies the company's ability to meet its immediate financial obligations without the need for additional financing. Additionally, the company operates with a moderate level of debt, which is a positive sign for risk-averse investors who are concerned about financial leverage.

For those interested in a deeper analysis, there are 11 additional InvestingPro Tips available for Apellis Pharmaceuticals, which can be accessed at InvestingPro. For a more comprehensive investment decision, readers can take advantage of the exclusive offer using coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.